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Abstract 
Background: Autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease are treated with TNF-
alpha-blocking antibodies such as infliximab and adalimumab. A common side effect of therapeutic antibodies is the 
induction of anti-drug antibodies, which may reduce therapeutic efficacy.
Methods: In order to reveal immunogenic epitopes on infliximab which are responsible for the adverse effects, sera 
from patients treated with infliximab were screened by ELISA for anti-infliximab antibodies. Sera containing high lev-
els of anti-drug-antibodies (>1.25 µg/ml) were analyzed in an oligopeptide microarray system containing immobilized 
15-meric oligopeptides from the infliximab amino acid sequence. Immunogenic infliximab IgG-epitopes were identi-
fied by infrared fluorescence scanning and comparison of infliximab-treated patients versus untreated controls.
Results: Six relevant epitopes on infliximab were recognized by the majority of all patient sera: 4 in the variable and 
2 in the constant region. Three of the epitopes in the variable region are located in the TNF-alpha binding region of 
infliximab. The fourth epitope of the variable part of infliximab is located close to the TNF-alpha binding region and 
contains an N-glycosylation sequon. The sera positive for anti-infliximab antibodies do not contain antibodies against 
adalimumab as determined by ELISA. Thus, there is no infliximab–adalimumab cross-reactivity as determined by these 
systems.
Conclusions: Our data shall contribute to a knowledge-based recommendation for a potentially necessary therapy 
switch from infliximab to another type of TNF-alpha-blocker. The characterization of immunogenic epitopes on 
therapeutic monoclonal antibodies using unprocessed patient sera shall lead to direct translational aspects for the 
development of less immunogenic therapeutic antibodies. Patients benefit from less adverse events and longer last-
ing drug effects.
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Background
Therapeutic monoclonal antibodies are a group of biolog-
ical drugs against diseases which are difficult to treat by 
“classical” small molecule drugs. These diseases include 
autoimmune disorders such as inflammatory bowel dis-
ease (IBD) and rheumatoid arthritis (RA) [1, 2]. The ther-
apeutic principle of these monoclonal antibodies in both 
disorders is the blockade of endogenous tumour necrosis 
factor α (TNF-α). By inhibiting TNF-α, the autoimmune-
inflammation cascade is interrupted, and the symp-
toms of the disease are suppressed [1, 3]. Yet, early on in 
monoclonal antibody therapy, adverse reactions such as 
hypersensitivity or reduced efficacy of biological drugs 
were observed [4–8]. These adverse reactions, induced 
by anti-drug antibodies (ADA) of different isotypes, 
were subject of numerous investigations, but the patho-
mechanisms including the immunological prerequisites 
that lead to these phenomena are not fully understood. 
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Immediate-type reactions with severe allergic symptoms 
and even fatal anaphylaxis are reported for cetuximab. 
In this case, the IgE-mediated pathomechanism involves 
an immune reaction towards the glycan galactose-α-
(1,3)-galactose, termed α-Gal on this chimeric anti-
body [9]. ADA are also involved in the reduced efficacy 
of therapeutic antibodies which may result in clinical 
non-responsiveness [10–12]. These ADA frequently 
develop during the course of therapy. Furthermore, it has 
also been shown that there are pre-existing antibodies 
against biologicals in some individuals [8, 13, 14]. For-
eign murine epitopes in the variable region of chimeric 
antibodies like infliximab (IFX) may well be responsible 
for the formation of ADA. Moreover, despite the elimina-
tion of chimeric epitopes of therapeutic antibodies by so-
called antibody humanization, there is still a number of 
patients who develop ADA [15]. Medical consequences 
of ADA formation may either be increase of dosage and/
or application frequency of the therapeutic antibody, dis-
continuation of the treatment or a switch to another type 
of biological drug [16].
In this study, a microarray-based chip system was 
established that allows the screening of serum IgG from 
unprocessed patient sera. Immunogenic epitopes in the 
variable region of infliximab were identified by epitope 
mapping of 20 sera from infliximab-treated patients. 
Although there are first reports indicating that neu-
tralizing ADA are directed against the TNF-α binding 
region of infliximab (IFX) [17], the exact immunogenic 
sequences in the complementary-determining region of 
IFX are determined in this study. To address the ques-
tion of a possible therapy switch, cross-reactivity of the 
infliximab-reactive sera with an alternative therapeu-




Sera of patients included in this study were sent from a 
clinical laboratory (16 samples) or a gastroenterologist 
(4 samples). The mean age of the patients was 37  years 
with 60 % females (Table 1). The mean anti-IFX antibody 
level was 51 µg/ml. The control group consists of healthy 
individuals from Northern Germany. 75  % are females 
(10/15), and the average age of this group is 35. Serum 
levels of anti-IFX antibodies in the control group were 
below the detection limit (<1.25 µg/ml).
ELISA measurement of anti‑infliximab/anti‑adalimumab 
antibodies in patient sera
The anti-IFX serum antibody titer was determined by a 
heterogeneous bridging ELISA test (IPM Biotech). For 
this test, a 96-well microtiter plate (Nunc maxisorp, 
VWR) was coated with 3  µg/ml of IFX per well for 2  h 
at 37  °C. After washing 3× with PBS buffer (50  mM, 
pH 7.4), wells were refilled with 50  µl Tris buffer (1  M, 
pH 9.5). 100  µl of diluted patient sera (1:10) were acid-
treated to dissolve potential immune complexes (100 mM 
acetic acid, 5 min, RT) and pipetted into the Tris-buffer-
containing wells. The microtiter plate was incubated at 
4 °C overnight. The following day, the wells were washed 
3× with PBS (50 mM) and 65 µl of acetic acid (100 mM) 
were pipetted into each well. After a 5 min incubation at 
RT on a shaker, 50 µl of the acid-treated fractions were 
transferred onto an untreated plate containing 50 µl Tris 
buffer (1  M, pH 9.5) per well. After an incubation time 
of 60  min (RT), the wells were washed 3× with PBS-
Tween (2.5  % v/v, PBST) and filled with 200  µl block-
ing buffer (5 % BSA, 5 % Casein in PBST). After another 
60 min of incubation at RT and 3× washing with PBST, 
10  µl biotinylated IFX (0.25  µg/ml) were added to each 
well. After 60  min rocking at RT and 3× washing with 
PBST, 100  µl streptavidin (0.5  µg/ml) conjugated with 
horseradish peroxidase (HRP) were added to each well, 
followed by another 15  min rocking at RT and wash-
ing 3× with PBST before 100 µl of TMB substrate were 
added. For colour development, the plate was incubated 
for 5 min at RT in the dark and the reaction was stopped 
by addition of 100 µl sulphuric acid (1 M) per well. The 
plates were analysed by an ELISA reader (Dynex, MRX) 
at wavelengths of 450 and 630  nm. All analyses were 
performed in duplicate. Anti-IFX standards (quantifica-
tion range 80–1.25  µg/ml) were run on each microtiter 
plate. The analysis of anti-ADL antibodies was performed 
accordingly except for the use of a biotinylated anti-ADL 
reagent.
Analysis of serum rheumatoid factors
IgA, IgM and IgG rheumatoid factors were determined 
by a commercial ELISA assay according to the manufac-
turer’s instructions (4027 RF IgA, 4046 RF IgM, 4085 RF 
IgG, GA Generic Assays).
Generation of infliximab oligopeptide microarrays
15-mer peptides derived from the amino acid sequence 
of IFX (drug bank acc. no. DB00065, Fig. 1) were synthe-
sized by Fmoc solid phase synthesis on amine-derivatized 
Table 1 Characteristics of IFX-treated patients and untreated 
healthy controls
y years, ADA anti-drug antibody
Patients Untreated controls
Mean age 37 y 35 y
Gender distribution 60 % female 75 % female
Mean ADA level 51 µg/ml <1.25 µg/ml
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cellulose disks of 2.7 mm diameter (Intavis Bioanalytical 
Instruments AG) using an automated multiple peptide 
synthesizer (MultiPep RS, Intavis Bioanalytical Instru-
ments AG). For this, the cellulose membrane disks were 
mounted into 384-well-footprint synthesis frames, and 
Fmoc protecting groups present on the amine functions 
of the disks were removed by treating each disk (3×) 
with 4 µl of 20 % (v/v) piperidine in dimethylformamide 
(DMF). Subsequent washing of the deprotected disks was 
performed 4× with 35 µl of DMF and 6× with 50 µl of 
ethanol each. Fmoc-protected amino acid derivatives 
were pre-activated by converting them into their corre-
sponding oximes. This was achieved by adding a 1.1  M 
solution of diisopropyl carbodiimide (DIC) in DMF to a 
solution containing 0.4  M  N-α-Fmoc-protected amino 
acid and 0.7  M ethyl-cyanoglyoxylate-2-oxime (Oxyma 
Pure, Merck) in DMF. The resulting final concentration 
was 0.25 M DIC, 0.2 M N-α-Fmoc-protected amino acid 
and 0.35 M Oxyma pure. Coupling of pre-activated amino 
acid derivatives to cellulose disks was accomplished by 
applying 1  µl of these solutions to the respective cellu-
lose disks. Coupling at each disk was repeated 3× and a 
minimum of 30 min of reaction time was allowed in each 
synthesis cycle. After coupling, unreacted amino groups 
were capped with 4  µl of 5  % (v/v) acetic anhydride in 
DMF (5  min, RT) before the next synthesis cycle was 
started by removal of the Fmoc groups. After comple-
tion of the peptide synthesis, the disks were treated 4× 
for 5 min with 4 µl of a solution of 20 % (v/v) piperidine 
in DMF, and the liberated amino termini were acetylated 
3× for 5  min with 4  µl of a 5  % (v/v) mixture of acetic 
anhydride in DMF at RT. The disks were washed 7× with 
35 µl of DMF followed by six washes with 50 µl of EtOH 
each before they were air-dried by application of vac-
uum suction for 12 min and transferred to 96-well plates 
(MegaBlock 96 well 2.2 ml; Sarstedt). Side chain protect-
ing groups of the peptides were cleaved by treatment 
with 150  µl of cleavage cocktail (80  % of trifluoroacetic 
Fig. 1 IFX-derived peptides used for oligopeptide array construction and analysed by epitope mapping of IFX-treated patient sera. 15-meric 
oligopeptides derived from the amino acid sequence of IFX with an offset of two amino-acids and random internal standardization peptides were 
spotted on cellulose-coated slides
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acid, TFA), 12 % of dichloromethane (DCM) 5 % of water 
and 2.5 % of triisobutylsilane [TIBS) (v/v)] per well for 2 h 
at RT. Subsequently, the cleavage cocktail was removed, 
and the disks were treated with 250 µl of cellulose lyse-
solution containing 88.5 % of TFA, 4 % of trifluorometh-
ane sulfonic acid (TFMSA) 5  % of water and 2.5  % of 
TIBS for 10 min on an ultrasound bath and for additional 
16  h under continuous shaking. After disintegration of 
the disks, 750  µl of cold tert-butylmethylether (TBME) 
were added and mixtures were kept at −20 °C for 90 min 
to precipitate the dissolved matter. Liquids were care-
fully removed and precipitates were resuspended 2× in 
750  µl of MTBE per well. MTBE was removed and the 
precipitates were dissolved in 500 µl of DMSO per well 
by treating the suspensions in the microwell plates for 
10 min on an ultrasound bath and by an additional 16 h 
continuous shaking. Plates were centrifuged (2800×g, 
5  min, Haeraeus Megafuge 1.0 R) for 10  min and 40  µl 
of the supernatant from each well were transferred to a 
384 well microtiter plate. 40 µl of SSC buffer (SSC buffer: 
3 M NaCl (175 g/L), 0.3 M sodium citrate·2H2O (88 g/L), 
adjusted to pH 7.0 with 1 M HCl, diluted 1:20 with water) 
were added to each well, the plates were sealed with an 
adhesive lid and treated on an ultrasound bath for 5 min. 
Peptide-modified cellulose solutions were transferred 
to cellulose-coated glass slides (Intavis Bioanalytical 
Instruments AG) using a slide-spotting robot (AutoSpot 
ASP222, Abimed Analysentechnik). A volume of 0.06 µl 
for each peptide was spotted in duplicate onto the slides 
in two arrays with 384 positions each (16  ×  24 spots, 
1.2 × 1.2 mm grid). Slides were air-dried and stored dry 
at −20 °C.
Epitope mapping of anti‑infliximab serum IgG
To identify IgG binding epitopes on IFX, the oligopeptide 
microarrays were probed with IFX-reactive patient sera 
(Table  2). The slides were allowed to thaw for 10  min, 
rehydrated with 100 % ethanol for 10 min on a horizon-
tal shaker at RT and washed 3× with TBST (Tris-buff-
ered saline, 50  mM, pH 7.4, Tween, 2.5  %) for 10  min. 
Slides were blocked with casein buffer (5 % in H2O) for 
4 h under shaking at RT. After washing for 10 min with 
TBST, patient sera were applied in a dilution of 1:500 in 
blocking buffer according to previous optimizations of 
patient serum and secondary antibody concentrations. 
Serum incubation was performed overnight at 4  °C on 
a horizontal shaker. Next, the slides were washed 6× 
for 10  min with TBST. The secondary antibody (anti-
human-IgG (H + L), IRDye 800 CW fluorophore, Li-Cor 
Biosciences GmbH) was applied in a dilution of 1:500 
in blocking buffer and incubated for 2  h. After washing 
6× for 10 min, the slides were dried and read-out using 
an infrared imager (Li-Cor, Odyssey, intensity 1, 42  µm 
resolution, high quality setting). The whole epitope map-
ping process was performed in three independent experi-
ments in duplicate for the 20 anti-IFX-positive patient 
sera and the 14 untreated control sera.
Microarray data analysis and statistics
Quantitation of the fluorescence signals was performed 
using Odyssey, version 2.1.12 (Licor Biosciences). Further 
data analysis and statistics was conducted with Microsoft 
Excel (MS Office 2013). A positive signal was defined as 
a positive fluorescence intensity value after subtraction 
of the mean background intensity plus threefold stand-
ard deviation derived from the random peptides on each 
microarray slide. This yields a probability of  >99  % of 
positivity for a positive signal [18]. Each of these posi-
tive signals was counted for the ADA positive sera as well 
as for the controls and plotted as frequency distribution 
against the IFX amino acid sequence to identify immu-
nogenic IFX epitopes (Fig. 1). A sequence was defined as 
a relevant epitope when at least 50 % of the analysed sera 
were positive for the respective motif (i.e. at least 10 for 
IFX-treated patient sera and 7 for negative helathy con-
trol sera). In case of overlapping sequences, the “local 
most-recognized sequence” with the highest number of 
positive sera reactions was identified.
Results
Detection of ADA against infliximab in sera 
from IFX‑treated patients
A heterogeneous bridging ELISA system was used 
to screen sera for ADA against infliximab. Sera were 
obtained from patients who experienced a suspected 
neutralization of drug efficacy during IFX treatment. 20 
ADA-positive patients, 8 male and 12 female, aged from 
4 to 80 years, were identified by the ELISA analyses. The 
specific ADA levels in those sera were in a concentration 
range of 14.4 µg/ml to more than 80 µg/ml with the latter 
being the upper limit of detection (Table  2). ADA con-
centrations of sera from 14 untreated healthy controls 
were consistently below the assay’s lower detection limit 
of 1.25 µg/ml.
Distinct IgG epitopes of anti‑infliximab‑positive sera 
determined by oligopeptide microarray epitope mapping
To obtain information about immunogenic epitopes, an oli-
gopeptide microarray epitope mapping system was estab-
lished. The sequence of the variable region of IFX (drug 
bank acc. no. DB00065) along with the heavy chain con-
stant region was synthesized chemically as 15-meric oligo-
peptides with an offset of two amino acids (13 amino acids 
overlap). These peptides were spotted onto a functionalized 
microarray slide. The microarrays were incubated with 20 
ADA-positive and 14 control sera from untreated, healthy 
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subjects each. Serum IgG binding was assessed with a fluo-
rophore-labelled antibody against human IgG and analysed 
by fluorescence imaging. For positive signal identification 
a statistical procedure was used that warrants >99 % prob-
ability for a positive signal by comparison with the mean 
background intensity derived from random peptides on 
each slide [18]. Positive signals were compiled for all sera 
and plotted against the IFX sequence to identify relevant 
immunogenic IFX epitopes (Fig.  2). A peptide sequence 
was considered a relevant epitope if at least 50  % of the 
analysed sera were positive for this sequence. In case of 
overlapping sequences in a recognition cluster, the peptide 
sequence with the highest number of positive serum reac-
tions was identified. Motif clusters that were designated as 
relevant epitopes are indicated by dashed lines (Fig. 2). Of 
the six relevant epitopes identified, four are located in the 
variable region of IFX (IFX 1–4) and two in the constant 
region (IFX 5 and 6). Epitopes IFX 1 and IFX 2 reside on 
the variable part of the heavy chain of IFX while IFX 4 is 
located in the variable light chain. These three epitopes are 
part of the complementary-determining region (CDR) of 
the IFX-TNF-α interaction site (Fig. 3) [19]. The light chain 
epitope IFX 3 is located close to CDR L3 and contains a 
glycosylation sequon at position N41. Interestingly, also 
epitope IFX 6 being situated in the constant region of the 
heavy chain contains a glycosylation sequon: the conserved 
human IgG1 glycosylation site N299. Epitope IFX 5 is also 
located in the constant region of the heavy chain. The bind-
ing frequencies of the patient sera against each epitope 
were varying: While IFX 4 just met the recognition fre-
quency threshold of 50 % (10/20) with IFX-treated patient 
sera, IgG from all ADA sera bound to epitope IFX 2 (20/20, 
Fig.  3). Surprisingly, the recognition of IFX epitopes was 
not restricted to IFX-treated patient sera. Particularly pro-
nounced recognition of epitopes by control sera occurred 
for IFX 2 and 3 with 9/14 and 13/14 control sera binding, 
respectively (Fig. 2).
IgG from IFX‑treated patient serum binds stronger to the 
identified IFX epitopes than IgG from untreated healthy 
controls
According to ELISA analyses, sera from IFX-treated 
patients resulted in a positive ADA ELISA signal, whereas 
untreated control sera were negative. Yet, some of the 
untreated control sera showed reactivity with certain IFX 
epitopes, especially pronounced against the epitopes IFX 2 
and 3 which are located in the variable region of IFX. The 
question arose if there are differences in “patient epitopes” 
vs. “control epitopes”. In order to further specify the char-
acteristics of the epitopes, a semi-quantitative analysis of 
the antibody binding strength in the microarray system 
was performed. For this, the mean fluorescence intensity 
Table 2 ADA levels in sera from patients treated with IFX and untreated healthy controls
Specific anti-drug-antibody (ADA) levels gainst IFX were determined by ELISA. The ADA detection range is 1.25–80 µg/ml
–, patient information not available
Patient ID Age Gender ADA (µg/ml) Control ID Age Gender ADA (µg/ml)
438 29 M 54.1 P* 48 F <1.25
452 30 F 63.9 F10 20 M <1.25
485 64 F 74.1 F22 25 F <1.25
522 42 F 45.9 F28 22 M <1.25
587 41 F 78.4 F31 45 M <1.25
609 30 M >80 F32 59 F <1.25
623 57 F 53.9 F33 25 F <1.25
626 57 F 44.1 F38 53 F <1.25
638 32 M 39.3 F41 19 M <1.25
639 33 M 47.4 F42 32 M <1.25
648 4 F 34.2 F43 31 F <1.25
652 31 M 29.7 F44 44 F <1.25
660 26 M 14.4 F45 36 F <1.25
681 – – 24.1 F46 35 F <1.25
694 13 F 45.6 F47 33 F <1.25
695 37 M 59.9
719 16 F 69.7
721 – – >80
722 42 M 44.8
724 80 F 32.6
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Fig. 2 Epitope mapping of IFX peptide microarrays with ADA-positive patient sera. Six relevant epitopes were identified. An epitope was desig-
nated as relevant when at least 50 % of the analysed sera showed a positive reaction (Y axis scale adjusted accordingly). IFX epitope mapping was 
performed three times in duplicate. One representative result is shown
Fig. 3 Structure of the IFX Fab fragment interaction with TNF-α. The identified IFX epitopes are located in or in close proximity to the IFX CDR 
involved in TNF-α binding. The mapped epitopes of the IFX variable segment of the heavy chain are indicated in yellow and orange (IFX 1 and 2), the 
light chain epitopes are shown in blue and red (IFX 3 and 4). The amino acids with direct contact to TNF-α in the CDR of IFX are indicated by black 
letters in the epitope sequences. Boxed N41 in epitope IFX 3 is part of a glycosylation sequon
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obtained in the epitope mapping experiments for each rele-
vant IFX epitope was calculated for the IFX-treated patient 
group and the untreated healthy controls (Fig.  4). The 
results show that antibody binding to the relevant epitopes 
is more pronounced in the IFX-treated patient sera than in 
the controls. This could be either due to a larger amount of 
ADA or a higher affinity of those antibodies. The stronger 
ADA array signals from IFX-treated patient sera as com-
pared to the low signals from untreated controls is in line 
with the ADA ELISA results. According to the ELISA, high 
reactivity against the complete IFX molecule was observed 
in samples from IFX-treated patients as opposed to nega-
tive results with untreated healthy control sera.
Anti‑infliximab serum antibodies do not bind to the 
constant region of infliximab as determined by ELISA 
rheumatoid factor analysis
As the majority of IFX-treated patient sera recognize at 
least one epitope in the constant region (IFX 5 and/or 6) 
serum rheumatoid factors (RF) including isotypes IgM, 
IgA and IgG were analysed by a commercial RF ELISA 
system (Table  3). The test results were negative for all 
isotypes and sera except for patient sera 438 and 648 and 
control serum F 46 which showed moderate (30.7, 27.5 
and 24.4 U/ml) IgG binding (Table 3). Serum F44 showed 
a positive IgA RF signal of 28.3 U/ml. However, this sig-
nal was not high above the threshold (25 U/ml) for IgA. 
IgM and IgG RF were negative for F44.
No cross‑reaction of anti‑infliximab serum antibodies 
with adalimumab as determined by anti‑adalimumab 
ELISA
As development of ADA may entail termination of an 
IFX therapy, it is important to know whether a switch to 
other TNF-α-blockers such as adalimumab (ADL) is fea-
sible. To address this question, the reactivity of the IFX-
treated patient sera to ADL was analyzed in an anti-ADL 
antibody ELISA assay (Table 4). As a result, none of the 
IFX-treated patient sera showed any anti-ADL antibody 
content above the assay’s detection limit (1.25  µg/ml). 
Control sera were also consistently negative for anti-ADL 
antibodies (<1.25 µg/ml).
Discussion
Several studies have shown that anti-drug-antibodies 
(ADA) are induced in a substantial number of patients 
who are treated with therapeutic monoclonal antibodies. 
It is assumed that the formation of ADA in such patients 
is responsible for several side effects reported for thera-
peutic antibodies [20, 21]. Whether or not ADA develop 
in a patient is dependent on various factors such as the 
therapeutic antibody itself, application route, dosage, fre-
quency of application, and the immunological history of 
patients with or without co-medication [1, 2, 4, 5, 15, 22]. 
All of these factors are classical parameters in vaccine 
development—not surprisingly, since ADA induction 
can be considered as an undesired immunization event. 
A key parameter in every immunization/vaccination 
effort is the immunogenicity of the antigen administered. 
Immunogenicity is governed by the physical status of 
the antigen (aggregate/monomer), its valency (mono- or 
multivalent) and the presence of B and T cell epitopes. In 
addition, cross-recognition caused by pre-existing immu-
nity against a similar antigen may also play a role.
This study aims to shed light on the immunogenicity 
of the therapeutic anti-TNF-α-antibody IFX, a widely 
used drug for the treatment of TNF-α-dependent auto-
immune disorders. We wanted to identify the most 
prominent immunogenic elements of IFX by using ADA-
containing patient sera along with a chip-based oligo-
peptide epitope mapping technology. In contrast to a 
previous study where linear peptide motifs were allowed 
to adsorb directly onto a solid support—a situation noto-
rious for low sensitivity—and which was performed with 
processed patient sera [23], our oligopeptide microarray 
epitope mapping system used cellulose-anchor equipped 
peptides instead and operated with non-processed 
patient sera. This more physiological setup revealed six 
prominent linear epitopes on IFX (Fig. 2). Two of these 
epitopes are located in the Fc part of the immunoglobu-
lin in the constant region of the heavy chain (IFX 5 and 
6) which is of human IgG1-origin. As humanization is 
considered the silver bullet to low immunogenicity of 
antibody drugs, this observation is disconcerting at first 
glance. However, the existence of immunoglobulin allo-
types and the occurrence of auto-antibodies against 
the constant regions of immunoglobulins (rheumatoid 
Fig. 4 IgG antibodies from IFX-treated patient sera bind stronger to 
IFX epitopes than serum IgG from untreated healthy controls. Mean 
signal intensity of antibody-binding of IFX-treated patient serum and 
serum from untreated healthy controls to identified IFX epitopes 
(Fig. 2). Results of three independent epitope mapping experiments, 
each performed in duplicate, are shown. AU, arbitrary units
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factors; RF) substantiate the conceivability for such a type 
of reaction. In fact, serum antibodies against the constant 
region of the heavy chain of IFX have been described [24, 
25]. On the other hand, both epitopes IFX 5 and 6 might 
not be accessible for antibody-binding on intact, correctly 
folded IFX [26], and—furthermore—IFX 6 contains the 
conserved IgG1 HC glycosylation site and thus may be 
camouflaged by the attached glycan on IFX in its native 
state. The almost complete absence of RF in the tested 
IFX-treated patient sera supports these hypotheses. The 
four other identified epitopes are located in the variable 
region of IFX. This result is not surprising as potentially 
immunogenic murine peptide sequences are located in 
this area. According to our study, ADA-binding occurs 
most frequently in the CDRs of IFX. Although this is 
highly unfortunate from the clinical point of view, it pro-
vides a conclusive explanation for the observed decline 
in IFX efficacy upon ADA formation. Epitopes IFX 1, 2 
and 4 display amino acids which are directly involved in 
TNF-α-binding. Binding of ADA to these peptides will 
most certainly impair the interaction of IFX with TNF-α. 
Consequently, the therapeutic efficacy of IFX may decline 
along with an increase in ADA [11]. Of special interest 
as a clinical biomarker for adverse patient reactions may 
be epitope IFX 2 as all of the investigated patient sera 
contained antibodies against this epitope. Epitope IFX 3, 
which is also located in the variable region, is also inter-
esting in several respects: Even though it is not directly 
involved in the TNF-α–IFX-interaction, its vicinity 
to CDR L2 may be sufficient to interfere with TNF-α-
binding. While in the case of IFX 1, 2 and 4 the ADA may 
compete directly with TNF-α in IFX-binding, the mode 
of action of ADA bound to IFX 3 may be one of steric 
hindrance. The presence of an N-glycosylation sequon in 
IFX 3 is another interesting feature. We can only specu-
late whether or not this site is glycosylated in the native 
IFX antibody. Indications are that this site may not be 
glycosylated [26]. As the non-glycosylated peptide IFX 3 
is recognized by 17 out of 20 patient sera, glycosylation at 
this position is not a prerequisite for recognition by ADA. 
Yet, it could still be possible that an N-glycan structure, 
which is part of IFX 3 in the native molecule, is co-rec-
ognized by ADA, and that ADA-reactivity towards this 
epitope would be markedly increased upon glycosylation. 
The non-glycosylated epitope IFX 3 is also recognized 
by a high number of control sera. Although the healthy 
individuals providing those sera have not been treated 
with IFX, they obviously harbour antibodies against this 
Table 3 Rheumatoid factor (RF) ELISA analysis of ADA-positive IFX-treated patients and ADA-negative untreated healthy 
control sera
RF ELISA results are considered being negative when below 10 U/ml for IgM, 25 U/ml for IgA, and 20 U/ml for IgG antibodies
nd not determined
Patient ID RF (U/ml) Control ID RF (U/ml)
IgM IgA IgG IgM IgA IgG
438 1.1 1.4 30.7 P* 2.0 3.4 8.4
452 5.1 2.8 5.0 F10 3.5 6.5 15.0
485 1.4 1.8 6.2 F22 1.9 2.3 14.2
522 1.7 3.2 16.4 F28 nd nd nd
587 3.3 2.0 3.6 F31 2.3 1.8 7.2
609 3.8 9.1 18.3 F32 3.1 18.9 5.7
623 3.1 8.1 10.2 F33 3.9 3.4 7.4
626 2.9 8.2 9.4 F34 1.3 2.4 8.4
638 2.7 2.8 4.7 F38 2.8 5.2 10.3
639 2.7 2.3 5.0 F41 2.2 2.0 10.3
648 2.3 11.4 27.5 F42 1.5 3.2 13.1
652 1.9 7.8 12.3 F44 3.5 28.3 11.3
660 2.2 3.4 12.3 F45 0.9 0.2 3.4
681 1.3 12.2 8.7 F46 2.2 3.5 24.4
694 2.9 3.3 10.2 F47 nd nd nd
695 2.9 4.0 14.5
719 1.1 8.8 7.4
721 2.7 0.9 4.1
722 4.4 4.5 3.3
724 0.9 21 4.8
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motif. One possible explanation for this phenomenon 
would be an immunogenetic/immunologic predisposi-
tion, i.e. a high rate of anti-IFX 3 paratopes in the naive 
B-cell repertoire or a pre-existing immunity against the 
peptide sequence (or a very similar one) of IFX 3. The 
question of a potential predisposition against therapeu-
tic antibodies is still a subject of debate [8, 13, 14]. In 
this context, one interpretation of our results would be 
an IFX-independent, pre-existing immunity against a 
peptide sequence related to IFX 3. Likewise, a potential 
pre-existing immunity against IFX 2 and a subsequent 
boost of this reactivity upon IFX treatment is in line with 
our data. Such an explanation would also be supported 
by the different affinities of the “patient” and “control” 
antibodies against these two epitopes, as indicated by the 
differing fluorescence signal intensities (Fig.  4). The lat-
ter may also explain the negative ADA ELISA results for 
the untreated healthy control sera in contrast to the posi-
tive results obtained with the IFX-treated patient sera. 
However, regarding pre-existing antibodies, the limit of 
detection of the used anti-IFX antibody ELISA detection 
system has to be taken into account. The sensitivity of 
the system is rather low (<1.25 µg/ml) compared to other 
ELISA systems (25–500 ng/ml), but thus also leads to a 
lower rate of false positive results. That means that only 
patients with a considerable amount of anti-IFX antibod-
ies are diagnosed as ADA positive. A disadvantage is the 
difficult detection of pre-existing low level ADA or the 
monitoring of the ADA development from low amounts 
to higher serum levels. It has to be mentioned that ADA 
of the subclass IgG4 cannot be detected by the bridging 
ELISA ADA detection system used in this study. Due to 
an intermolecular Fab arm exchange IgG4 is monovalent. 
Yet, this ELISA system reflects the present diagnostic sit-
uation for the detection of anti-drug antibodies (ADA).
Conclusions
Our data indicate a host-borne drug neutralization by 
ADA which are directed against the CDR of IFX, i.e. the 
TNF-α-binding regions. Those sites are not present in 
other anti-TNF-α antibodies. The results of this study 
shall lead to a better understanding of the development 
of anti-biological antibodies and to a knowledge-based 
suggestion for a safe and efficacious switch to another 
antibody during anti-TNF-α therapy. In this context, the 
oligopeptide microarray technique could become a useful 
tool for treatment monitoring with a special emphasis on 
the early detection of ADA development to biologicals. 
The screening platform may lead to the development of 
less immunogenic therapeutic antibodies in the future 
from which patients will benefit in terms of reduced 
adverse events and longer lasting drug effects.
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Table 4 Cross-reactivity analysis of ADA
IFX-treated patient sera positive for anti-IFX antibodies and untreated healthy 
control sera were analyzed in an ELISA system for anti-adalimumab (ADL) 
antibody detection
Patient ID Age Anti‑ADL  
(µg/ml)
Control ID Age Anti‑ADL 
(µg/ml)
438 29 <1.25 P* 48 <1.25
452 30 <1.25 F10 20 <1.25
485 64 <1.25 F22 25 <1.25
522 42 ≤1.25 F28 22 <1.25
587 41 <1.25 F31 45 <1.25
609 30 <1.25 F32 59 <1.25
623 57 <1.25 F33 25 <1.25
626 57 <1.25 F38 53 <1.25
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652 31 <1.25 F44 44 <1.25
660 26 <1.25 F45 36 <1.25
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